Van den Eynde Benoit
Van den Eynde Benoit
Director, Brussels Branch of the Ludwig Institute for Cancer Research; Professor of Immunology, Univ. catholique de Louvain, de
Verified email at
Cited by
Cited by
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
P van der Bruggen, C Traversari, P Chomez, C Lurquin, E De Plaen, ...
Science 254 (5038), 1643-1647, 1991
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase
C Uyttenhove, L Pilotte, I Théate, V Stroobant, D Colau, N Parmentier, ...
Nature medicine 9 (10), 1269-1274, 2003
Tumor antigens recognized by T lymphocytes
T Boon, JC Cerottini, B Van den Eynde, P van der Bruggen, A Van Pel
Annual review of immunology 12 (1), 337-365, 1994
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
PG Coulie, BJ Van den Eynde, P Van Der Bruggen, T Boon
Nature Reviews Cancer 14 (2), 135-146, 2014
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.
B Gaugler, B Van den Eynde, P van der Bruggen, P Romero, JJ Gaforio, ...
The Journal of experimental medicine 179 (3), 921-930, 1994
Human T cell responses against melanoma
T Boon, PG Coulie, BJV Eynde, P Bruggen
Annu. Rev. Immunol. 24, 175-208, 2006
T cell defined tumor antigens
BJ Van den Eynde, P Van Der Bruggen
Current opinion in immunology 9 (5), 684-693, 1997
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.
B Van den Eynde, O Peeters, O De Backer, B Gaugler, S Lucas, T Boon
The Journal of experimental medicine 182 (3), 689-698, 1995
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion
M Platten, W Wick, BJ Van den Eynde
Cancer research 72 (21), 5435-5440, 2012
Tumor antigens recognized by T cells
T Boon, PG Coulie, B Van den Eynde
Immunology today 18 (6), 267-268, 1997
Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase
L Pilotte, P Larrieu, V Stroobant, D Colau, E Dolušić, R Frédérick, ...
Proceedings of the National Academy of Sciences 109 (7), 2497-2502, 2012
Tumor‐specific shared antigenic peptides recognized by human T cells
P Van Der Bruggen, Y Zhang, P Chaux, V Stroobant, C Panichelli, ...
Immunological reviews 188 (1), 51-64, 2002
Classification of current anticancer immunotherapies
L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ...
Oncotarget 5 (24), 12472, 2014
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
S Morel, F Lévy, O Burlet-Schiltz, F Brasseur, M Probst-Kepper, ...
Immunity 12 (1), 107-117, 2000
An antigenic peptide produced by peptide splicing in the proteasome
N Vigneron, V Stroobant, J Chapiro, A Ooms, G Degiovanni, S Morel, ...
Science 304 (5670), 587-590, 2004
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.
B Van den Eynde, B Lethe, A Van Pel, E De Plaen, T Boon
The Journal of experimental medicine 173 (6), 1373-1384, 1991
Molecular and translational classifications of DAMPs in immunogenic cell death
AD Garg, L Galluzzi, L Apetoh, T Baert, RB Birge, BS Pedro, J Manuel, ...
Frontiers in immunology 6, 169354, 2015
Extensive profiling of the expression of the indoleamine 2, 3-dioxygenase 1 protein in normal and tumoral human tissues
I Théate, N van Baren, L Pilotte, P Moulin, P Larrieu, JC Renauld, C Hervé, ...
Cancer immunology research 3 (2), 161-172, 2015
Rational design of indoleamine 2, 3-dioxygenase inhibitors
UF Röhrig, L Awad, A Grosdidier, P Larrieu, V Stroobant, D Colau, ...
Journal of medicinal chemistry 53 (3), 1172-1189, 2010
Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
AD Garg, PG Coulie, BJ Van den Eynde, P Agostinis
Trends in immunology 38 (8), 577-593, 2017
The system can't perform the operation now. Try again later.
Articles 1–20